Blue Cell Therapeutics ApS Financials, key figures and credit report
Gross profit -5 780.6 kDKK FY 2025 -89.4% vs 2024
EBIT -20 619.7 kDKK FY 2025 -17.5% vs 2024
Net debt 325.5 kDKK FY 2025 +104.3% vs 2024
Quick ratio 0.4 FY 2025 -13.1 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | - 843.70 | 852.13 | - 741.53 | -3 052.65 | -5 780.57 |
| Employee benefit expenses | -8 474.46 | -11 642.95 | -14 195.72 | -12 785.68 | -11 125.12 |
| Other operating expenses | -5 845.13 | -3 735.73 | -2 986.32 | -1 539.57 | -3 598.36 |
| Total depreciation | - 218.68 | - 273.58 | - 335.32 | - 163.37 | - 115.64 |
| EBIT | -15 381.97 | -14 800.13 | -18 258.89 | -17 541.26 | -20 619.69 |
| Other financial expenses | -51.45 | -64.46 | -3.51 | -9.98 | -14.03 |
| Reduction non-current investment assets | -3 808.57 | ||||
| Pre-tax profit | -15 433.43 | -14 864.59 | -18 262.41 | -17 551.25 | -24 442.29 |
| Income taxes | 1 192.02 | 2 294.63 | 2 974.03 | 2 361.40 | 3 221.17 |
| Net earnings | -14 241.41 | -12 569.96 | -15 288.37 | -15 189.85 | -21 221.12 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Machinery and equipment | 602.06 | 328.48 | 269.50 | 176.71 | 61.07 |
| Tangible assets total | 602.06 | 328.48 | 269.50 | 176.71 | 61.07 |
| Investments total | 56.24 | 103.80 | 82.60 | 122.60 | 122.60 |
| Long term receivables total | |||||
| Inventories total | |||||
| Current trade debtors | 138.84 | ||||
| Prepayments and accrued income | 6.46 | 118.65 | 36.77 | 99.84 | 13.12 |
| Current other receivables | 576.14 | 1 477.86 | 3 164.73 | 3 809.65 | 1 215.75 |
| Current deferred tax assets | 2 157.02 | 4 451.65 | 2 973.95 | 2 361.32 | 3 221.09 |
| Short term receivables total | 2 739.62 | 6 187.00 | 6 175.45 | 6 270.81 | 4 449.97 |
| Cash and bank deposits | 10 606.82 | 4 005.38 | 3 631.63 | 7 554.32 | 190.28 |
| Cash and cash equivalents | 10 606.82 | 4 005.38 | 3 631.63 | 7 554.32 | 190.28 |
| Balance sheet total (assets) | 14 004.74 | 10 624.66 | 10 159.19 | 14 124.45 | 4 823.92 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 40.00 | 43.13 | 47.46 | 53.75 | 53.75 |
| Retained earnings | 26 682.62 | 22 438.08 | 23 659.95 | 28 230.54 | 13 040.68 |
| Profit of the financial year | -14 241.41 | -12 569.96 | -15 288.37 | -15 189.85 | -21 221.12 |
| Shareholders equity total | 12 481.21 | 9 911.25 | 8 419.03 | 13 094.43 | -8 126.69 |
| Non-current liabilities total | |||||
| Current loans from credit institutions | 515.78 | ||||
| Current trade creditors | 885.33 | 327.89 | 668.23 | 573.82 | 1 023.31 |
| Other non-interest bearing current liabilities | 638.19 | 385.51 | 1 071.92 | 456.20 | 11 411.52 |
| Current liabilities total | 1 523.53 | 713.41 | 1 740.15 | 1 030.02 | 12 950.61 |
| Balance sheet total (liabilities) | 14 004.74 | 10 624.66 | 10 159.19 | 14 124.45 | 4 823.92 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated